n*n
2 楼
富马酸二甲酯,
这么简单的药物,当初怎么发现的?
专利没有问题吗
这么简单的药物,当初怎么发现的?
专利没有问题吗
p*u
4 楼
Dimethyl fumarate has won FDA approval to treat relapsing-remitting forms of
multiple sclerosis and will be sold under the name Tecfidera, the agency
said Wednesday.
Manufactured by Biogen Idec, the drug is also known as BG-12. It becomes the
third oral disease-modifying medication available to treat MS. Others
include fingolimod (Gilenya) and teriflunomide (Aubagio).
Dimethyl fumarate has a novel mechanism of action relative to existing MS
drugs. It is believed to activate the nuclear factor-like 2 transcriptional
pathway, thereby reducing oxidative stress that contributes strongly to
demyelination.
The drug has also been used for many years in Europe and elsewhere to treat
psoriasis, and has also been used as a fungicide and desiccant in furniture
manufacture.
Two placebo-controlled phase III trials served as the basis for approval,
the agency said. Called DEFINE and CONFIRM, they enrolled a total of some 2,
700 patients. In addition to comparing the drug with placebo, CONFIRM
included a third arm with open-label glatiramer acetate (Copaxone), a
standard injectable MS drug.
Both trials demonstrated that dimethyl fumarate was superior to placebo in
preventing relapses and delaying disability progression. It also appeared to
be somewhat more effective than glatiramer acetate in CONFIRM.
The most common adverse effects were gastrointestinal complaints and
flushing. The FDA also noted that the drug carries a risk of lymphocytopenia
, although infections did not appear to be increased as a result in the
phase III studies.
"No drug provides a cure for multiple sclerosis so it is important to have a
variety of treatment options available for patients," said Russell Katz, MD
, director of the Division of Neurology Products in the FDA's Center for
Drug Evaluation and Research, in a statement announcing the approval.
A Biogen competitor, Teva Pharmaceuticals, had petitioned the FDA to hold an
advisory committee meeting on the drug before approving it, citing the
hematologic effects and other risks, but the agency declined to do so.
http://www.medpagetoday.com/Neurology/MultipleSclerosis/38122?i
multiple sclerosis and will be sold under the name Tecfidera, the agency
said Wednesday.
Manufactured by Biogen Idec, the drug is also known as BG-12. It becomes the
third oral disease-modifying medication available to treat MS. Others
include fingolimod (Gilenya) and teriflunomide (Aubagio).
Dimethyl fumarate has a novel mechanism of action relative to existing MS
drugs. It is believed to activate the nuclear factor-like 2 transcriptional
pathway, thereby reducing oxidative stress that contributes strongly to
demyelination.
The drug has also been used for many years in Europe and elsewhere to treat
psoriasis, and has also been used as a fungicide and desiccant in furniture
manufacture.
Two placebo-controlled phase III trials served as the basis for approval,
the agency said. Called DEFINE and CONFIRM, they enrolled a total of some 2,
700 patients. In addition to comparing the drug with placebo, CONFIRM
included a third arm with open-label glatiramer acetate (Copaxone), a
standard injectable MS drug.
Both trials demonstrated that dimethyl fumarate was superior to placebo in
preventing relapses and delaying disability progression. It also appeared to
be somewhat more effective than glatiramer acetate in CONFIRM.
The most common adverse effects were gastrointestinal complaints and
flushing. The FDA also noted that the drug carries a risk of lymphocytopenia
, although infections did not appear to be increased as a result in the
phase III studies.
"No drug provides a cure for multiple sclerosis so it is important to have a
variety of treatment options available for patients," said Russell Katz, MD
, director of the Division of Neurology Products in the FDA's Center for
Drug Evaluation and Research, in a statement announcing the approval.
A Biogen competitor, Teva Pharmaceuticals, had petitioned the FDA to hold an
advisory committee meeting on the drug before approving it, citing the
hematologic effects and other risks, but the agency declined to do so.
http://www.medpagetoday.com/Neurology/MultipleSclerosis/38122?i
b*t
5 楼
等到下个statement也很正常
s*g
7 楼
你确定买的都是grocery店?
c*u
8 楼
walmart到底算不算,有个确切的答案吗
相关阅读
晓东也出来和大家抢钱了,呵呵投Nature快3周了,没消息版上的化学牛人们,问个壳寡糖的问题 (转载)有答案了,删掉。DEEP SEQUENCEING? ANY SUGGESTION专访:谢晓亮的科学人生发包子活跃一下气氛哈western blot formadehyde cross linked sample?Buffalo.调查 DUANQING PEIneed a paperThe 10 Best Jobs of 2011 (转载)请教一个网站可以查询小鼠和人类发育年纪对照的?今天有点郁闷请问如何去除革兰氏阳性细菌细胞表面的培养液?请教关于写review的通讯作者问题Thrombin切蛋白的奇怪事儿气死了--最近半年一直在做别人已经发表的东西果儿在哪里,肿瘤可能是寄生虫? (转载)